Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation
Tiantian Tang, Xueting Lang, Cong‐Fei Xu, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 307

Showing 26-50 of 307 citing articles:

Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction
Qiang Ma
Pharmacological Reviews (2023) Vol. 75, Iss. 3, pp. 487-520
Open Access | Times Cited: 93
The mechanism of NLRP3 inflammasome activation and its pharmacological inhibitors
Xiaoyan Zhan, Qiang Li, Guang Xu, et al.
Frontiers in Immunology (2023) Vol. 13
Open Access | Times Cited: 88
DAMPs and DAMP-sensing receptors in inflammation and diseases
Ming Ma, Wei Jiang, Rongbin Zhou
Immunity (2024) Vol. 57, Iss. 4, pp. 752-771
Open Access | Times Cited: 79
Inhibitors of the NLRP3 inflammasome pathway as promising therapeutic candidates for inflammatory diseases (Review)
Xiaolu Zhang, Ziyu Wang, Yujia Zheng, et al.
International Journal of Molecular Medicine (2023) Vol. 51, Iss. 4
Open Access | Times Cited: 59
LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer
Jiali Dai, Tianyu Qu, Dandan Yin, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 5
Open Access | Times Cited: 58
The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in diabetic retinopathy
Xiaoqin Zheng, Jia Wan, Gang Tan
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 57
New Insights on NLRP3 Inflammasome: Mechanisms of Activation, Inhibition, and Epigenetic Regulation
Triveni Kodi, Runali Sankhe, Adarsh Gopinathan, et al.
Journal of Neuroimmune Pharmacology (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 31
NLRP inflammasomes in health and disease
Zhihao Xu, Arnaud John Kombe Kombe, Shasha Deng, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 29
The role of NLRP3 inflammasome in type 2 inflammation related diseases
Xu Shenming, Dan Wang, Lina Tan, et al.
Autoimmunity (2024) Vol. 57, Iss. 1
Open Access | Times Cited: 25
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy
Fulin Zhou, Wenwen Lian, Xiaotang Yuan, et al.
Alzheimer s Research & Therapy (2025) Vol. 17, Iss. 1
Open Access | Times Cited: 5
NLRP3 inflammasome in health and disease (Review)
Haoran Wang, Li Ma, Weiran Su, et al.
International Journal of Molecular Medicine (2025) Vol. 55, Iss. 3
Closed Access | Times Cited: 2
Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation
Yi Li, Haitao Li, Shuai Liu, et al.
Molecular Immunology (2018) Vol. 99, pp. 134-144
Closed Access | Times Cited: 140
Target of MCC950 in Inhibition of NLRP3 Inflammasome Activation: a Literature Review
Danbin Wu, Yefei Chen, Yingxin Sun, et al.
Inflammation (2019) Vol. 43, Iss. 1, pp. 17-23
Closed Access | Times Cited: 125
Gypenosides improve diabetic cardiomyopathy by inhibiting ROS ‐mediated NLRP 3 inflammasome activation
Hailong Zhang, Xi Chen, Beibei Zong, et al.
Journal of Cellular and Molecular Medicine (2018) Vol. 22, Iss. 9, pp. 4437-4448
Open Access | Times Cited: 123
Development of small molecule inhibitors targeting NLRP3 inflammasome pathway for inflammatory diseases
Xiangna Zhang, Ana Xu, Jiahui Lv, et al.
European Journal of Medicinal Chemistry (2019) Vol. 185, pp. 111822-111822
Closed Access | Times Cited: 117
Salidroside Attenuates High‐Fat Diet‐Induced Nonalcoholic Fatty Liver Disease via AMPK‐Dependent TXNIP/NLRP3 Pathway
Tao Zheng, Xiaoyan Yang, Wenjin Li, et al.
Oxidative Medicine and Cellular Longevity (2018) Vol. 2018, Iss. 1
Open Access | Times Cited: 112
Ginsenoside Rd ameliorates colitis by inducing p62-driven mitophagy-mediated NLRP3 inflammasome inactivation in mice
Chao Liu, Jianing Wang, Yan Yang, et al.
Biochemical Pharmacology (2018) Vol. 155, pp. 366-379
Closed Access | Times Cited: 102
Intracellular Chloride Channels: Novel Biomarkers in Diseases
Shubha Gururaja Rao, Neel Patel, Harpreet Singh
Frontiers in Physiology (2020) Vol. 11
Open Access | Times Cited: 98
Targeting NLRP3 Inflammasome Activation in Severe Asthma
Efthymia Theofani, Maria Semitekolou, Ioannis Morianos, et al.
Journal of Clinical Medicine (2019) Vol. 8, Iss. 10, pp. 1615-1615
Open Access | Times Cited: 95
Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation
Monica Yabal, Dale J. Calleja, Daniel S. Simpson, et al.
Journal of Leukocyte Biology (2018) Vol. 105, Iss. 2, pp. 377-399
Open Access | Times Cited: 91
Therapeutic regulation of the NLRP3 inflammasome in chronic inflammatory diseases
Jin Kyung Seok, Han Chang Kang, Yong‐Yeon Cho, et al.
Archives of Pharmacal Research (2021) Vol. 44, Iss. 1, pp. 16-35
Open Access | Times Cited: 88
Inflammasome activation and Th17 responses
Jian Deng, Xiao‐Qiang Yu, Pei‐Hui Wang
Molecular Immunology (2019) Vol. 107, pp. 142-164
Closed Access | Times Cited: 82
Innate Immune Sensing of Influenza A Virus
Gaurav Malik, Yan Zhou
Viruses (2020) Vol. 12, Iss. 7, pp. 755-755
Open Access | Times Cited: 82
Distinct Molecular Mechanisms Underlying Potassium Efflux for NLRP3 Inflammasome Activation
Ziwei Xu, Zi-mo Chen, Xiaoyan Wu, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 80
The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout
Zoltán Szekanecz, Szilvia Szamosi, Gergő Kovács, et al.
Archives of Biochemistry and Biophysics (2019) Vol. 670, pp. 82-93
Closed Access | Times Cited: 77

Scroll to top